JP7669396B2 - 骨髄増殖性腫瘍の治療のための、ルキソリチニブとｉｎｃｂ０５７６４３との組合わせ - Google Patents

骨髄増殖性腫瘍の治療のための、ルキソリチニブとｉｎｃｂ０５７６４３との組合わせ Download PDF

Info

Publication number
JP7669396B2
JP7669396B2 JP2022574520A JP2022574520A JP7669396B2 JP 7669396 B2 JP7669396 B2 JP 7669396B2 JP 2022574520 A JP2022574520 A JP 2022574520A JP 2022574520 A JP2022574520 A JP 2022574520A JP 7669396 B2 JP7669396 B2 JP 7669396B2
Authority
JP
Japan
Prior art keywords
day
pharma
acceptable salt
pharmaceutical composition
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022574520A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529365A5 (cg-RX-API-DMAC10.html
JP2023529365A (ja
Inventor
シュトゥブス，マシュー
シー リウ，フィリップ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of JP2023529365A publication Critical patent/JP2023529365A/ja
Publication of JP2023529365A5 publication Critical patent/JP2023529365A5/ja
Priority to JP2025067272A priority Critical patent/JP2025111539A/ja
Application granted granted Critical
Publication of JP7669396B2 publication Critical patent/JP7669396B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022574520A 2020-06-03 2020-09-14 骨髄増殖性腫瘍の治療のための、ルキソリチニブとｉｎｃｂ０５７６４３との組合わせ Active JP7669396B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025067272A JP2025111539A (ja) 2020-06-03 2025-04-16 骨髄増殖性腫瘍の治療のための、ルキソリチニブとｉｎｃｂ０５７６４３との組合わせ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063034214P 2020-06-03 2020-06-03
US63/034,214 2020-06-03
PCT/US2020/050753 WO2021247064A1 (en) 2020-06-03 2020-09-14 Combination of ruxolitinib with incb057643 for treatment of myeloproliferative neoplasms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025067272A Division JP2025111539A (ja) 2020-06-03 2025-04-16 骨髄増殖性腫瘍の治療のための、ルキソリチニブとｉｎｃｂ０５７６４３との組合わせ

Publications (3)

Publication Number Publication Date
JP2023529365A JP2023529365A (ja) 2023-07-10
JP2023529365A5 JP2023529365A5 (cg-RX-API-DMAC10.html) 2023-09-22
JP7669396B2 true JP7669396B2 (ja) 2025-04-28

Family

ID=72659928

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022574520A Active JP7669396B2 (ja) 2020-06-03 2020-09-14 骨髄増殖性腫瘍の治療のための、ルキソリチニブとｉｎｃｂ０５７６４３との組合わせ
JP2025067272A Pending JP2025111539A (ja) 2020-06-03 2025-04-16 骨髄増殖性腫瘍の治療のための、ルキソリチニブとｉｎｃｂ０５７６４３との組合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025067272A Pending JP2025111539A (ja) 2020-06-03 2025-04-16 骨髄増殖性腫瘍の治療のための、ルキソリチニブとｉｎｃｂ０５７６４３との組合わせ

Country Status (23)

Country Link
EP (2) EP4161528B1 (cg-RX-API-DMAC10.html)
JP (2) JP7669396B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230031242A (cg-RX-API-DMAC10.html)
CN (1) CN115835868A (cg-RX-API-DMAC10.html)
AU (1) AU2020451061A1 (cg-RX-API-DMAC10.html)
CA (1) CA3184633A1 (cg-RX-API-DMAC10.html)
CL (1) CL2022003409A1 (cg-RX-API-DMAC10.html)
DK (1) DK4161528T3 (cg-RX-API-DMAC10.html)
ES (1) ES3058891T3 (cg-RX-API-DMAC10.html)
FI (1) FI4161528T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20251457T1 (cg-RX-API-DMAC10.html)
IL (1) IL298200A (cg-RX-API-DMAC10.html)
LT (1) LT4161528T (cg-RX-API-DMAC10.html)
MA (1) MA59868B1 (cg-RX-API-DMAC10.html)
MD (1) MD4161528T2 (cg-RX-API-DMAC10.html)
MX (1) MX2022015220A (cg-RX-API-DMAC10.html)
PH (1) PH12022553276A1 (cg-RX-API-DMAC10.html)
PL (1) PL4161528T3 (cg-RX-API-DMAC10.html)
PT (1) PT4161528T (cg-RX-API-DMAC10.html)
RS (1) RS67440B1 (cg-RX-API-DMAC10.html)
SI (1) SI4161528T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202600021T1 (cg-RX-API-DMAC10.html)
WO (1) WO2021247064A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025111539A (ja) * 2020-06-03 2025-07-30 インサイト・コーポレイション 骨髄増殖性腫瘍の治療のための、ルキソリチニブとｉｎｃｂ０５７６４３との組合わせ

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4297750A1 (en) * 2021-02-25 2024-01-03 Impact Biomedicines, Inc. Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis
WO2024039883A2 (en) * 2022-08-19 2024-02-22 Translational Drug Development Llc Compositions and methods to treat myeloproliferative disorders and myeloproliferative neoplasms
WO2024144258A1 (ko) * 2022-12-28 2024-07-04 주식회사 삼양홀딩스 룩소리티닙의 다중 방출제어 정제 조성물 및 이의 제조 방법
EP4734995A1 (en) * 2023-06-28 2026-05-06 Board of Regents, The University of Texas System Quinoline carboxamides for use in the treatment of mpn

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019524660A (ja) 2016-06-20 2019-09-05 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｂｅｔ阻害剤の結晶固体形態

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
SMT202000133T1 (it) * 2014-04-23 2020-05-08 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-oni e pirazolo[3,4-c]piridin-7(6h)-oni come inibitori di proteine bet
HRP20251457T1 (hr) * 2020-06-03 2026-01-02 Incyte Corporation Kombinacija ruksolitiniba s incb057643 za uporabu u liječenju mijeloproliferativnih neoplazmi

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019524660A (ja) 2016-06-20 2019-09-05 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｂｅｔ阻害剤の結晶固体形態

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FALCHOOK G et al.，Clinical Cancer Research，2020年03月，Vol. 26，No. 6，pp.1247-1257.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025111539A (ja) * 2020-06-03 2025-07-30 インサイト・コーポレイション 骨髄増殖性腫瘍の治療のための、ルキソリチニブとｉｎｃｂ０５７６４３との組合わせ

Also Published As

Publication number Publication date
JP2025111539A (ja) 2025-07-30
IL298200A (en) 2023-01-01
MD4161528T2 (ro) 2026-03-31
PH12022553276A1 (en) 2024-02-19
DK4161528T3 (da) 2025-11-24
JP2023529365A (ja) 2023-07-10
CL2022003409A1 (es) 2023-05-26
PT4161528T (pt) 2026-01-23
FI4161528T3 (fi) 2025-12-12
AU2020451061A1 (en) 2022-12-15
KR20230031242A (ko) 2023-03-07
PL4161528T3 (pl) 2026-03-16
EP4161528A1 (en) 2023-04-12
RS67440B1 (sr) 2025-12-31
HRP20251457T1 (hr) 2026-01-02
SI4161528T1 (sl) 2026-01-30
WO2021247064A1 (en) 2021-12-09
MX2022015220A (es) 2023-03-08
CN115835868A (zh) 2023-03-21
EP4691563A3 (en) 2026-04-01
CA3184633A1 (en) 2021-12-09
ES3058891T3 (en) 2026-03-13
SMT202600021T1 (it) 2026-03-09
EP4691563A2 (en) 2026-02-11
LT4161528T (lt) 2026-02-10
EP4161528B1 (en) 2025-11-05
MA59868B1 (fr) 2025-11-28

Similar Documents

Publication Publication Date Title
EP4161528B1 (en) Combination of ruxolitinib with incb057643 for use in the treatment of myeloproliferative neoplasms
US20260137695A1 (en) Combination therapy for treatment of myeloproliferative neoplasms
TWI702057B (zh) 盧梭利替尼之緩釋性劑型
AU2024323620A1 (en) Crystalline forms of a pi3k inhibitor and uses of same
CN116157403B (zh) 曲拉西利的形态及其制造方法
KR20190130644A (ko) 항암 조합 요법
CN118201615A (zh) 喹唑啉酮化合物用于治疗癌症的新用途
US11419862B2 (en) Quinoline derivative for treatment of nasopharyngeal carcinoma
TW201922256A (zh) 治療淋巴樣惡性疾病之方法
JP2025061387A (ja) 複素環式タンパク質キナーゼ阻害剤を含む製剤
CN115038447A (zh) 用于治疗癌症的组合疗法
US12318384B2 (en) Methods of treatment
KR20230144571A (ko) Serd 투여 요법의 조합을 사용하여 암을 치료하는 방법
US20230165863A1 (en) Methods and formulations for administration of thiocarbamate deriviatives a2a inhibitors
EP4197554A1 (en) Combined medication for treating soft tissue sarcoma
US12268786B2 (en) Methods of improving the solubility and bioavailability of therapeutic agents
WO2025094990A1 (en) Medicament for treating cancer comprising optically active azabicyclo ring derivative
TW202608439A (zh) 治療具有ａｓｘｌ１突變之個體之癌症的方法
HK40112620A (en) Novel use of quinazolinone compound for the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230912

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250318

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250416

R150 Certificate of patent or registration of utility model

Ref document number: 7669396

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150